WO2008129256A3 - Hiv therapy - Google Patents

Hiv therapy Download PDF

Info

Publication number
WO2008129256A3
WO2008129256A3 PCT/GB2008/001357 GB2008001357W WO2008129256A3 WO 2008129256 A3 WO2008129256 A3 WO 2008129256A3 GB 2008001357 W GB2008001357 W GB 2008001357W WO 2008129256 A3 WO2008129256 A3 WO 2008129256A3
Authority
WO
WIPO (PCT)
Prior art keywords
larg
inhibiting
expression
activity
cell
Prior art date
Application number
PCT/GB2008/001357
Other languages
French (fr)
Other versions
WO2008129256A2 (en
Inventor
Alison Simmons
Original Assignee
Isis Innovation
Alison Simmons
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation, Alison Simmons filed Critical Isis Innovation
Publication of WO2008129256A2 publication Critical patent/WO2008129256A2/en
Publication of WO2008129256A3 publication Critical patent/WO2008129256A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

A composition for inhibiting the expression and/or activity of the leukaemia-associated Rho guanine nucleotide exchange factor (LARG) and/or the Rho protein in a cell and its use in the manufacture of a medicament for the treatment of HIV infection, and a method of treating HIV infection by administering a composition capable of inhibiting the expression and/or activity of LARG and/or Rho protein to a cell or organism.
PCT/GB2008/001357 2007-04-18 2008-04-17 Hiv therapy WO2008129256A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0707429A GB0707429D0 (en) 2007-04-18 2007-04-18 HIV Therapy
GB0707429.7 2007-04-18

Publications (2)

Publication Number Publication Date
WO2008129256A2 WO2008129256A2 (en) 2008-10-30
WO2008129256A3 true WO2008129256A3 (en) 2009-06-04

Family

ID=38116896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/001357 WO2008129256A2 (en) 2007-04-18 2008-04-17 Hiv therapy

Country Status (2)

Country Link
GB (1) GB0707429D0 (en)
WO (1) WO2008129256A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013128025A1 (en) * 2012-03-01 2013-09-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rhogef12 is a therapeutic target for the treatment of heart failure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006104751A2 (en) * 2005-03-30 2006-10-05 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006104751A2 (en) * 2005-03-30 2006-10-05 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DUBASH ADI D ET AL: "A novel role for Lsc/p115 RhoGEF and LARG in regulating RhoA activity downstream of adhesion to fibronectin.", JOURNAL OF CELL SCIENCE 15 NOV 2007, vol. 120, no. Pt 22, 15 November 2007 (2007-11-15), pages 3989 - 3998, XP002504670, ISSN: 0021-9533 *
HODGES ASHLEIGH ET AL: "Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication.", NATURE IMMUNOLOGY JUN 2007, vol. 8, no. 6, June 2007 (2007-06-01), pages 569 - 577, XP002504669, ISSN: 1529-2908 *
WANG L ET AL: "Modulation of HIV-1 replication by a novel RhoA effector activity.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 MAY 2000, vol. 164, no. 10, 15 May 2000 (2000-05-15), pages 5369 - 5374, XP002504671, ISSN: 0022-1767 *
WANG QIN ET AL: "Ribozyme- and siRNA-mediated suppression of RGS-containing RhoGEF proteins.", METHODS IN ENZYMOLOGY 2004, vol. 389, 2004, pages 244 - 265, XP008098820, ISSN: 0076-6879 *
ZHENG R ET AL: "Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase.", ONCOGENE 28 SEP 2006, vol. 25, no. 44, 28 September 2006 (2006-09-28), pages 5942 - 5952, XP002504667, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
GB0707429D0 (en) 2007-05-23
WO2008129256A2 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
EP3150204A3 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
NZ596236A (en) Inhibitors of human immunodeficiency virus replication
NZ599298A (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
TW200621730A (en) Chemical compounds
TW200634003A (en) Chemical compounds
TW200616974A (en) Chemical compounds
MX2007008924A (en) Chemical compounds.
WO2007128817A3 (en) Insulin derivative
NZ587060A (en) Rna interference for the treatment of heart failure
MY170728A (en) Treatment for diabetes in patients inappropriate for metformin therapy
MX2007004882A (en) Xanthine derivatives with hm74a receptor activity.
TW200621259A (en) Chemical compounds
TW200606162A (en) Pyrazolopyridine derivatives
MY144616A (en) Substituted dihydroquinazolines
BRPI0513513A (en) compound or a pharmaceutically acceptable salt thereof, process for preparing it, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and methods for producing an eg5 inhibitory effect and an anticancer effect on a warm-blooded animal , and to treat carcinomas in a warm-blooded animal
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
EP1848418A4 (en) Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection
WO2007071958A3 (en) Combination of zd6474 and pemetrexed
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
WO2007072221A3 (en) Surface marker-directed cancer therapeutics
SI1594885T1 (en) Medicament for inhibiting tumour growth
TW200700411A (en) Heterocyclylamide-substituted imidazoles
TW200505880A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08737017

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08737017

Country of ref document: EP

Kind code of ref document: A2